X
[{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Abu Dhabi Growth Fund","pharmaFlowCategory":"D","amount":"$112.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neumora Therapeutics Announces $112 Million Series B Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"BlackThorn Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for Navacaprant
Filters
Companies By Therapeutic Area
Details:
NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for MDD.
Lead Product(s):
Navacaprant
Therapeutic Area: Psychiatry/Psychology
Product Name: NMRA-140
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
BlackThorn Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 18, 2023
Details:
The funding will support the advancement of a broad clinical and preclinical pipeline of novel precision medicine candidates including BTRX-335140 (NMRA-140) for neuropsychiatric disorders and neurodegenerative diseases and the development of precision neuroscience platform.
Lead Product(s):
Navacaprant
Therapeutic Area: Psychiatry/Psychology
Product Name: BTRX-335140
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Abu Dhabi Growth Fund
Deal Size: $112.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
October 11, 2022